Genome-wide association study to find modifiers for tetralogy of fallot in the 22q11.2 deletion syndrome identifies variants in the GPR98 locus on 5q14.3 by Guo, Tingwei et al.
1Background—The 22q11.2 deletion syndrome (22q11.2DS; DiGeorge syndrome/velocardiofacial syndrome) occurs in 1 
of 4000 live births, and 60% to 70% of affected individuals have congenital heart disease, ranging from mild to severe. 
In our cohort of 1472 subjects with 22q11.2DS, a total of 62% (n=906) have congenital heart disease and 36% (n=326) 
of these have tetralogy of Fallot (TOF), comprising the largest subset of severe congenital heart disease in the cohort.
Methods and Results—To identify common genetic variants associated with TOF in individuals with 22q11.2DS, we 
performed a genome-wide association study using Affymetrix 6.0 array and imputed genotype data. In our cohort, TOF 
was significantly associated with a genotyped single-nucleotide polymorphism (rs12519770, P=2.98×10−8) in an intron of 
the adhesion GPR98 (G-protein–coupled receptor V1) gene on chromosome 5q14.3. There was also suggestive evidence 
of association between TOF and several additional single-nucleotide polymorphisms in this region. Some genome-
wide significant loci in introns or noncoding regions could affect regulation of genes nearby or at a distance. On the 
basis of this possibility, we examined existing Hi-C chromatin conformation data to identify genes that might be under 
shared transcriptional regulation within the region on 5q14.3. There are 6 genes in a topologically associated domain of 
chromatin with GPR98, including MEF2C (Myocyte-specific enhancer factor 2C). MEF2C is the only gene that is known 
to affect heart development in mammals and might be of interest with respect to 22q11.2DS.
Conclusions—In conclusion, common variants may contribute to TOF in 22q11.2DS and may function in cardiac outflow 
tract development.  (Circ Cardiovasc Genet. 2017;10:e. DOI: 10.1161/CIRCGENETICS.116.001690.)
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One of the greatest challenges in the area of human genetics is to understand the basis of phenotypic heterogeneity in 
known diseases. The 22q11.2 deletion syndrome (22q11.2DS; 
velocardiofacial syndrome/DiGeorge syndrome; Mendelian 
Inheritance in Man No. 192430, 188400) is one of the most 
common genomic disorders, occurring in 1 of 4000 live births.1 
Over 90% of affected individuals have a de novo, hemizygous 
3 million base pair (Mb) deletion on chromosome 22q11.2.2–4 
All subjects with the deletion have features of the syndrome, 
See Editorial by McBride and Ware 
See Clinical Perspective
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but the clinical presentation is quite variable. For example, 
60% to 70% of patients have congenital heart disease (CHD) 
involving the cardiac outflow tract (OFT) and aortic arch, 
whereas the rest have apparently normal cardiac structures.5 
Among the most serious defect observed in individuals with 
the 22q11.2DS is tetralogy of Fallot (TOF), which is defined 
by the presence of a ventricular septal defect, pulmonary steno-
sis, overriding aorta, and right ventricular hypertrophy. TOF is 
caused in part by failed migration or differentiation of second 
heart field mesodermal cells from the pharyngeal apparatus in 
embryos, needed to form or remodel the cardiac OFT.6 TOF 
occurs in 1 of 2500 live births in the general population (Center 
for Disease Control and Prevention). Among individuals with 
the 22q11.2DS, 36% in our cohort has TOF, and among indi-
viduals with TOF, ≈15% have a 22q11.2 deletion.7,8
Among the genes in the deleted region on 22q11.2, TBX1, 
which encodes a T-box transcription factor, is the major can-
didate for CHD.9–11 Tbx1 is expressed in the second heart field 
mesoderm, which is disrupted in 22q11.2DS.9–11 Global inac-
tivation9–11 or second heart field–specific inactivation12 of Tbx1 
results in neonatal lethality with severe cardiac OFT defects. 
One hypothesis to explain variable phenotypic expression 
in the 22q11.2DS is the presence of pathogenic variants in 
TBX1 on the haploid allele of 22q11.2. Previously, we tested 
whether common or rare single-nucleotide variants (SNVs) in 
the coding region of TBX1 on the remaining allele of 22q11.2 
were associated with CHD in 22q11.2DS subjects, but we did 
not find an association.13 Another hypothesis is that there are 
copy number variations elsewhere in the genome that could 
explain differences in phenotypes. We previously found that 
a commonly occurring genomic duplication encompassing 
the glucose transporter gene, SLC2A3, was associated with 
CHD (P=2.68×10−4).14 This copy number variation occurred 
in 5.8% of individuals with 22q11.2DS and CHD and 1.1% of 
those with 22q11.2DS and no CHD. Recently, a partial dupli-
cation of a chromatin modifier, KANSL1, was associated with 
CHD in a Chilean 22q11.2DS cohort.15 However, these copy 
number variations occurred in only some deleted subjects with 
CHD and thus do not explain the basis of phenotypic variabil-
ity in the majority of patients.
Our goal was to identify common single-nucleotide poly-
morphisms (SNPs) that are associated with TOF in individuals 
with 22q11.2DS. We restricted our analyses to TOF because it 
is the largest single phenotypic category of severe CHD in our 
cohort. Restricting our analyses in this way may reduce het-
erogeneity in the genes that contribute to CHD in individuals 
with 22q11.2DS and thus may increase the power of a GWAS.
Methods
Human Subjects and Phenotype Data
We assembled a cohort of subjects with 22q11.2DS (Tables I and II 
in the Data Supplement). Subjects were previously recruited by the 
International Chromosome 22q11.2DS Consortium, the International 
22q11.2 Brain Behavior Consortium (http://22q11-ibbc.org), and 
clinical groups that specialize in the treatment of individuals with 
22q11.2DS. All subjects within the cohort had a clinical diagnosis of 
22q11.2DS that was confirmed by the presence of a 22q11.2 deletion 
using fluorescence in situ hybridization or multiplex ligation-depen-
dent probe amplification (SALSA MLPA kit P250 DiGeorge; MRC 
Holland, The Netherlands). Informed consent was obtained for all 
participants, and this study was conducted under an Internal Review 
Board-approved protocol at the Albert Einstein College of Medicine 
(CCI 1999-201).
For this study, we used previously collected genomic DNA and 
phenotypic and demographic information. We obtained echocardio-
gram and cardiology reports to confirm the specific CHD diagnosis 
(eg, TOF).
SNP Array Genotype and Data Quality Control
Genomic DNA from 1244 study subjects was array genotyped us-
ing Affymetrix GeneChip Genome-Wide SNP 6.0 array. The major-
ity of samples were genotyped was at the Genomics Facility core 
laboratory of Albert Einstein College of Medicine. However, 37 
samples were genotyped in the Advanced Genomics laboratory core 
at the Children’s Research Institute (Milwaukee, WI) for clinical 
purposes,16 and 191 Chilean samples were genotyped in the Center 
for Human Genetics, Clínica Alemana Universidad del Desarrollo, 
Santiago, Chile.15
The raw data from all arrays were processed through the same pipeline 
using the same criteria. Genotype data from arrays with contrast quality 
control scores ≤0.4 per sample, contrast quality control <1.7 per batch, 
and Median Absolute Pairwise Difference metric >0.35, were excluded. 
Genotypes were called using the Birdseed V2 Genotyping Algorithm 
(call rate: 99.02±0.02%). To account for batch effects, BEAGLECALL 
Version 1.0.1 software was used to rescore genotypes.17 SNPs with call 
rates <95%, minor allele frequency <1%, or Hardy–Weinberg equilib-
rium P value <10−5 were excluded. In addition, samples that showed 
second-degree relatedness or closer, based on identity by state, were re-
moved. For each subject, deletion size was determined using the log2 
intensity ratio as estimated by the Copy Number Analysis Module of 
Golden Helix Powerseat Package. The CEL files and genotype data are 
being deposited to National Center for Biotechnology Information data-
base of Genotypes and Phenotypes phs001339.v1.p1.
We performed imputation to increase the number of SNPs 
available for analysis. Only genotyped SNPs with minor allele fre-
quency >1% were used for imputation. Haplotypes were prephased 
using SHAPEIT software,18,19 and imputation was performed using 
IMPUTE2 with the 1000 Genomes Phase I data set as the reference 
panel.20 Imputed SNPs with minor allele frequency ≤1% or imputa-
tion quality (INFO) scores ≤0.8 were excluded from the GWAS.
Statistical Methods
We used a case–control approach, in which individuals with 
22q11.2DS and TOF were considered cases and individuals with 
22q11.2DS without CHD were considered controls. We conducted 
principal component analyses to identify the PCs of race/ethnicity. 
Potential associations between TOF, sex, and deletion size were as-
sessed using logistic regression adjusted for the first 4 PCs. A P value 
<0.05 was considered significant.
The association between TOF and each SNP was assessed by 
logistic regression analysis under an additive genetic model using 
data from all study subjects. These analyses were performed using 
SNPTEST v2.5.2 https://mathgen.stats.ox.ac.uk/genetics_software/
snptest/snptest.html) and accounted for the genotyping accuracy 
and first 4 PCs of race/ethnicity.21,22 A P value of 5×10−8 was used 
as the genome-wide significance cutoff for single association tests. 
For a meta-analysis, the cohort was split into groups determined by 
principal component analyses. Each group was analyzed separately 
using logistic regression, and the results were meta-analyzed using 
the inverse-variance method. Power for these analyses was assessed 
using QUANTO (http://biostats.usc.edu/Quanto.html). Manhattan 
plots and quantile–quantile (Q–Q) plots were generated using Golden 
Helix Powerseat. For regions of interest identified in the GWAS, re-
gional association plots were generated using LocusZoom software 
(http://locuszoom.sph.umich.edu/locuszoom/).23
Conditional logistic regression analyses were performed to de-
termine whether multiple variants within a region are independently 
associated with TOF in individuals with 22q11.2DS. Specifically, 
within a region, we conditioned on the genotyped SNP with the 
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lowest P value and the first 4 principal components of race/ethnicity 
and individually evaluated the association of TOF with each addi-
tional SNP in the region. Conditional analyses were conducted using 
SNPTEST v2.5.2.
Linkage Disequilibrium Analysis of Whole-
Genome Sequence to Identify Variants in Linkage 
Disequilibrium With GWAS Findings
Whole-genome sequencing of a subset (n=397) of our 22q11.2DS 
samples was performed using the Illumina HiSeq2000 and HiSeq 
X Ten platform at Hudson Alpha Institute for Biotechnology 
(Huntsville, Alabama) as part of the International 22q11.2 Brain 
and Behavior Consortium to find genes for schizophrenia. Variant 
calling was performed using PEMapper software for read mapping 
to the hg38 (GRCh38) reference genome and PECaller software for 
variant calling.24 CrossMap (http://crossmap.sourceforge.net/) was 
used to convert genome coordinates between hg38(GRCh38) and 
hg19 (GRCh37).25 To follow-up on the top result from the GWAS 
(Results), the genomic region (chromosome 5 [chr5]:88 703 723–
91 409 593) from MEF2C through ARRDC3 was extracted from the 
whole-genome sequencing data. Functional annotation of SNVs 
was performed using the Variant Classification and the Annotate 
and Filter tools in the Golden Helix software. Nonexonic SNVs (in-
tronic, intergenic) were removed, and predicted functional SNVs 
were used to generate an linkage disequilibrium (LD) matrix using 
Haploview. LD measurements of r2 >0.8 were used to define LD 
haplotype blocks.
Mouse Embryo Analysis and Whole-Mount RNA In 
Situ Hybridization
Gene expression profiling was previously performed to identify 
differentially expressed genes in the second heart field mesoderm 
of wild-type mouse embryos.12 Data from wild-type embryos were 
extracted for evaluation of specific expression levels in this tissue. 
For in situ hybridization, RNA probes were generated from mouse 
embryo cDNA using digoxigenin-uridine triphosphate (Roche 
Diagnostic Corp, Indianapolis, IN; Table III in the Data Supplement). 
Swiss Webster strain wild-type mouse embryos were isolated at day 
(E)9.5 or E10.5 and used for experiments.
Results
Description of the 22q11.2DS Population
A total of 1472 unrelated subjects with 22q11.2DS were ascer-
tained through multiple sources (Tables I and II in the Data 
Supplement) and were genotyped on Affymetrix 6.0 arrays. 
Genotypes (n≈6.6 million SNPs with minor allele frequency 
>0.01 and INFO>0.8) were also imputed.
The characteristics of the study subjects are shown in 
Table 1. These subjects predominantly self-reported as white 
and non-Hispanic (Table 1). This was confirmed by principal 
component analyses using 4 PCs (we did not observe a differ-
ence between usage of 4 or 10 PCs) to estimate genetic ances-
try (Figure I in the Data Supplement). The majority (191/217) 
of Hispanic subjects were recruited at the collection site in 
Santiago, Chile. Approximately 62% of the subjects (n=906) 
had CHD at birth. There are 4 sets of low copy repeats, termed 
LCR22A, B, C, and D, that span the 22q11.2 region. All of the 
subjects had a deletion of 1 allele of TBX1, which is located in 
the LCR22A-B interval, and the majority of subjects had the 
typical 3 Mb deletion flanked by LCR22A-D (Table 1; Table 
IV in the Data Supplement). In this cohort, neither sex nor 
deletion size were significantly associated with CHD in gen-
eral or with TOF specifically (P>0.05).
GWAS to Identify Genetic Loci for TOF
The TOF phenotype comprised the largest individual group of 
subjects with severe intracardiac anomalies in our 22q11.2DS 
population (36%; Table 1; Figure 1). We conducted a GWAS 
to identify genetic variants associated with TOF. This analy-
sis was based on data from 326 subjects with 22q11.2DS and 
TOF and 566 subjects with 22q11.2DS and normal cardiac 
anatomy. This study had a power of 80% to detect an odds 
ratio of >1.9 for a common SNP with an allele frequency >0.3 
under a log-additive model at P <5×10−8.
Subjects of all races and ethnicities were included, and 
associations were assessed using logistic regression adjusted 
with the first 4 PCs of race/ethnicity. As neither deletion size 
nor sex was significantly associated with TOF in this cohort, 
these variables were not included in the logistic models. The 
genomic inflation factor (λ=1.02) and the Q–Q plot (Figure II 
in the Data Supplement) provided little evidence of a system-
atic deviation from the expected distribution of the test statistic.
Three SNPs mapping to intron 61 of GPR98 (G-protein–
coupled receptor 98) were significantly associated with 
TOF. The genotyped SNP, rs12519770 (P=2.98×10−8), 
Table 1. Characteristics of Study Subjects
Subject Characteristics n (%)
Self-reported race
  White 1229 (83)
  Black 34 (2)
  Asian 11 (0.7)
  Native American 1 (<0.1)
  Mixed Ancestry 20 (1)
  Unknown 177 (12)
Self-reported ethnicity
  Non-Hispanic 1255 (85)
  Hispanic 217 (15)
Sex
  Male 717 (49)
  Female 754 (51)
  Unknown 1 (<0.1)
Congenital heart defect
  TOF 326 (22)
  Other CHD 580 (39)
  Normal (controls) 566 (38)
Deletion size
  Typical 3 Mb (LCR22A-D) 1366 (93)
  Nested LCR22A-B 73 (5)
  Nested LRC22A-C 26 (2)
  Other 12 (1)
The cohort of 1472 samples is shown categorized based on self-reported 
race, ethnicity, and sex. The numbers and percentages in each category are 
indicated. A total of 906 subjects have congenital heart disease (CHD), whereas 
the rest have normal structures. The deletion sizes are indicated. LCR indicates 
low copy repeats; and TOF, tetralogy of Fallot.
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and imputed SNPs, rs7720206 (P=2.22×10−8) and chr5: 
90 067 043:D (P=2.10×10−8), showed the strongest associa-
tion (Figure 2A, Table 2). These three SNPs seem to be in 
complete LD (Figure 2B and 2C). For rs12519770, the A 
allele was the risk allele with a frequency of 0.58 in TOF 
cases and 0.45 in controls, conferring an odds ratio of 1.69 
(P=3.2×10−8) per copy of the A allele in the 22q11.2DS 
cohort (Table 2; Figure 2). There was also suggestive evi-
dence of association between TOF and 2 additional groups 
of SNPs in GPR98. The top genotyped SNP in each cluster 
(rs6889138, rs6893710) is listed in Table 2 and illustrated in 
Figure 2B and 2C.
Although our initial GWAS adjusted for the first 4 PCs of 
race/ethnicity, the observed associations may still reflect bias 
because of uncontrolled confounding resulting from popula-
tion stratification. Consequently, we repeated our analyses for 
the top SNP, rs12519770, after separating the cohort into 3 
groups: white, Admixed, and African, as determined by prin-
cipal component analyses (Figure I in the Data Supplement). 
The P value for this SNP was significant in the meta-analysis 
(P=4.43×10−8; Table V in the Data Supplement), suggesting 
that the observed association is unlikely to be the result of 
population stratification.
Within the 5q14.3 region, there seemed to be 3 clusters 
of SNPs that were associated with TOF. We refer to these as 
clusters 1, 2, and 3, and the clusters are ranked in ascend-
ing order based on the P value for the top SNP within the 
cluster. To determine whether >1 variant was independently 
associated with TOF, we performed conditional analyses in 
which we conditioned on the genotyped SNP in GPR98 with 
the smallest P value in cluster 1 (rs12519770; P=2.98×10−8) 
and individually evaluated the association of TOF with each 
of the additional SNPs in the 5q14.3 region (n=1344 SNPs, 
Table VI in the Data Supplement). In these conditional analy-
ses, there was suggestive evidence for association with 1 SNP 
(rs6893710, P=3.92x10−5). This variant was the top SNP in the 
third cluster of associated genes (Table 2). The association of 
the top SNP in the second cluster (rs6889138) was attenuated 
in the conditional analysis (P=0.002).
Definition of the 5q14.3 Locus
To identify nonsynonymous variants that may be in LD with the 
rs12519770 and to narrow the region containing the association 
signal on 5q14.3 based on LD, we performed an LD analysis 
using existing whole-genome sequence data from 397 individ-
uals with 22q11.2DS (http://22q11-ibbc.org; unpublished data, 
International 22q11.2 Brain and Behavior Consortium authors 
in Supplementary Table 1,  2017). These individuals comprise 
a subset of the samples genotyped on Affymetrix 6.0 arrays and 
were selected based on psychiatric but not cardiovascular phe-
notype. There were 9680 SNVs identified in the 2.7 Mb region 
around GPR98 (chr5: 8 799 640–90 704 983). There were 161 
coding SNVs (102 nonsynonymous, 58 synonymous, and 1 
splicing) and 115 SNVs in the 3ʹ or 5ʹ-untranslated regions 
for a total of 276 SNVs (Table VII in the Data Supplement). 
None of these SNVs were in LD with rs12519770. The SNP, 
rs6893710, was in weak LD with the synonymous variant, 
rs41304884 (GPR98, NM_032119.3, c.16164G>A;Dʹ=0.859, 
r2=0.389; Figure 2B). There were no nonsynonymous variants 
related to our association signal.
Most GWAS signals that have been previously discovered 
are in intergenic regions and may mark transcriptional regu-
latory regions in the genome rather than genes themselves. 
To test this for TOF in 22q11.2DS, we examined the LD pat-
tern from available whole-genome sequencing data on the 
same 397 22q11.2DS subjects to narrow the interval with 
SNPs showing the strongest association. We narrowed down 
the association signal to a 104.7 kb region on chromosome 5 
(chr5: 90 057 563–90 162 285; Figure 2C and 2D, red block). 
Most of the common SNPs with P values <10−5 were located 
in this region (Figure 2C). A similar LD pattern has been 
observed in the white subset from the 1000 Genomes Project 
(Figure III in the Data Supplement). Thus, we were able to 
narrow the region of the association signal.
Genes Mapping to 5q14.3
Because the SNPs found within the intron of GPR98 might 
affect its regulation or, instead, the regulation of other genes 
in the region, we examined local chromosome conforma-
tion forming topologically associated domains (TADs).26–28 
To investigate higher-order chromatin-mediated looping, we 
extracted data for the 5q14.3 interval from the Hi-C browser.29 
There was chromatin interaction data for 28 different cell lines 
ranging from H1 embryonic stem cells to cancer cell lines.29–
31
 We focused on TAD contact domains in a 3.3 Mb region 
including GPR98 (Figure 3; Figure IV in the Data Supple-
ment). Because the 104.7 kb region with genetic association is 
within the GPR98 locus, it is possible that variants might affect 
its expression or that of nearby genes. In addition to GPR98, 
this region includes 6 additional genes (Figure 3; Figure IV 
in the Data Supplement), including 5 protein coding genes 
within the 2.3 Mb TAD: MEF2C (Myocyte enhancer factor 
2C), CETN3 (Centrin 3), MBLAC2 (Metallo-β-lactamase 
domain containing 2), POLR3G (RNA polymerase III sub-
unit G), and LYSMD3 (LysM, putative peptidoglycan-binding, 
domain containing 3). One gene, ARRDC3 (Arrestin domain 
Figure 1. Distribution of cardiovascular phenotypes in 1472, 
22q11.2 deletion syndrome (22q11.2DS) subjects. The number 
of subjects (y axis) sorted into phenotypes (x axis) is shown in 
the bar graph. All individuals have a hemizygous 22q11.2 dele-
tion. The most serious cardiovascular diagnoses with the largest 
number of subjects is tetralogy of Fallot (TOF; n=326; black bar) 
among a total with congenital heart disease (CHD; n=906; gray 
bar) when compared with those with no intracardiac or aortic 
arch anomalies as detected by echocardiogram summary and 
cardiology report (white bar).
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Figure 2. Genome-wide association results for tetralogy of Fallot (TOF) in 22q11.2 deletion syndrome (22q11.2DS). A, Values in the Man-
hattan plot for TOF vs controls were plotted against their respective positions on the autosomal chromosomes. The red line represents the 
genome-wide significance threshold (P=5×10−8). The blue line represents the threshold for suggestive association (P=1×10−5). A single locus 
marked by the GPR98 (G-protein–coupled receptor V1) gene reached genome-wide significance. B, LD matrix of selected, predicted func-
tional SNPs with top P values on the 5q14.3 region from WGS (Methods). The LD with respect to associated single-nucleotide polymor-
phisms (SNPs) with highest P values in the region is shown. The LD plot is based on r2 values. Key: r2=0 is given in white, 0<r2<1 is given in 
shades of grey and r2=1 is given in black. The pairwise Dʹ values are provided in the boxes. Nine SNPs are in modest LD (Dʹ=0.80, r2=0.23) 
with rs12519770. The G allele of the top genotyped SNP, rs6889138, located in intron 74 of GPR98 and had a minor allele frequency (MAF) 
of 0.30 in TOF cases, and 0.21 in controls giving an odds ratio (OR) of 1.68 (P=1.72×10−7) per copy in the 22q11.2DS cohort. There were 
14 SNPs in the second group that had suggestive association with TOF and were in modest LD with SNP, rs12519770 (Dʹ=0.84, r2=0.02). 
The top SNP, rs6893710, is located in intron 47 of GPR98 and had a MAP of 0.058 in TOF cases, but 0.015 in controls, giving an OR of 
4.05 (P=1.04×10−6) per copy of the C allele in the 22q11.2DS cohort (Table 2). C, LocusZoom plot of region of association at rs12519770 on 
5q14.3 indicating −log10 P values (y axis) against the chromosomal positions of SNPs (x axis). The genotyped (Continued )
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containing 3), maps downstream of GPR98, but it is in a dif-
ferent TAD (Figure 3). The same domain structure marked 
by TAD triangles occurred in most of the cell lines that were 
examined (Figure IV in the Data Supplement).
We next determined whether any of the genes are 
expressed in the pharyngeal apparatus or heart in embryos. 
Probes were generated, and in situ hybridization was suc-
cessfully performed for Gpr98, Cetn3, Lysmd3, and Mef2c 
in mouse embryos at E9.5 and E10.5, when the cardiac 
OFT is expanding (Figure 3). Although Gpr98 is weakly 
expressed at E9.5, it is strongly expressed in the neural 
tube region, particularly the hindbrain32 (Figure 3). Cetn3, 
important in the cilia33 for centrosome reproduction,34 and 
Lysmd3, of unknown function, are ubiquitously expressed, 
although Cetn3 has lower expression levels in the heart itself 
(Figure 3). Mef2c encodes a MADS box transcription fac-
tor, and it is expressed in the pharyngeal apparatus including 
the second heart field mesoderm,35 as indicated in Figure 3. 
Among the genes in the TAD, MEF2C is the only one spe-
cifically expressed in cardiac progenitor cells known to be 
required for heart development.36
The second heart field mesodermal progenitor cell popu-
lations forming the cardiac OFT lie within the distal pha-
ryngeal apparatus. We then examined expression levels of 
genes in the 5q14.3 region in existing Affymetrix microarray 
data from the microdissected distal pharyngeal apparatus.12 
The purpose was to determine whether any of the genes are 
expressed in this critical tissue. We compared expression 
levels of genes on 5q14.3 to the highest expressed genes 
(Actb, Gapdh), Tbx1 expression, and the lowest expressed 
genes (Il6, Olfr299) in this tissue as shown in Figure 3C. 
All of the genes are expressed in the pharyngeal apparatus, 
albeit Gpr98 is expressed at the lowest level, as can be also 
seen in Figure 3B.
The Encyclopedia of DNA Elements functional genomics 
data were examined in the 104.7 kb region of LD with SNP, 
rs12519770, to identify possible regulatory regions. We found 
3 possible regulatory regions defined by binding of multiple 
transcription factors, with one close to rs12519770 (Figure V 
in the Data Supplement). None of the SNPs that were geno-
typed in our study lie within these putative regulatory regions; 
however, critical embryonic regulatory regions could be dif-
ferent, and they have not yet been defined.
Discussion
We identified genome-wide significant associations between 
TOF and several SNPs in an intron of GPR98 in our 22q11.2DS 
cohort. We narrowed the associated region to a 104.7 kb inter-
val. This interval may harbor functional variants that are in LD 
with the associated SNPs or noncoding variants that regulate 
the expression of genes within a broad TAD on 5q14.3.
GPR98 contains 90 exons, spans over 610 kb, and encodes 
a member of the adhesion-G protein-coupled receptor family 
of receptors. The GPR98 protein binds calcium and is weakly 
expressed early in mouse embryonic development at E9.5, 
but it becomes more strongly expressed in the future brain 
and neural tube by E10.5. It is the largest of the 7-transmem-
brane receptors and has important functions in hearing and 
vision.37,38 Recessive mutations cause Usher syndrome type 2C 
(Mendelian Inheritance in Man No. 605472), which is charac-
terized by congenital hearing loss and progressive retinitis pig-
mentosa.39 There are multiple splice variants present in GPR98, 
and it is not known if all isoforms have similar functions. Thus, 
it is possible that ≥1 splice variants could have a function in 
neural crest cells deriving from the neural tube. Neural crest 
cells are a migratory population of progenitor cells in the pha-
ryngeal apparatus, which contribute to cardiac OFT septation. 
There are no reports of a possible function of GPR98 in the car-
diovascular system and no known connections to human TOF.
CETN3 is another gene of note in the 5q14.3 region because 
it encodes a centrin protein that functions in the cytoskeleton 
of centrosomes and cilia.40 Cilia are critically important for 
conferring left right assymetry during embryonic develop-
ment and when disrupted is associated with human cardiac 
anomalies22 Because laterality defects are not commonly 
found in association with 22q11.2DS, more work would need 
Table 2. Top SNPs in GPR98 Associated With TOF
SNP Chr:Position (bp) Cluster
Risk 
Allele
Other 
Allele RAF OR (95% CI) P Value
Conditional  
P Value*
Conditional
P Value†
rs12519770 5:90073277 1 A G 0.5 1.69 (1.39–2.06) 2.98E-08 NA NA
rs6889138 5:90335635 2 G A 0.24 1.68 (1.35–2.10) 1.72E-07 0.00199523 NA
rs6893710 5:90058041 3 C T 0.03 4.05 (2.27–7.24) 1.04E-06 3.92E-05 6.11E-05
The top genotyped single-nucleotide polymorphisms (SNPs) in each cluster of SNPs identified for tetralogy of Fallot (TOF) are shown. Chr:Position (bp), chromosome 
and positions are indicated according to NCBI36/hg18 (March 2006), and allele coding was based on the positive strand. The cluster numbers that the SNPs belong to 
are indicated. GPR98 indicates G-protein–coupled receptor V1; NA, not associated; OR, odds ration; and RAF, risk allele frequency in the whole cohort.
*Conditional P value: analysis was conditioned on SNP rs12519770.
†Conditional P value: individually evaluated the association of TOF with 1344 SNPs in the 5q14.3 region (Table VI in the Data Supplement).
Figure 2 Continued. SNP with the strongest association signal in each locus is represented as a purple diamond; the other SNPs are 
colored according to the extent of LD (correlation r2 is based on CEU HapMap haplotypes) with this SNP. Estimated recombination rates 
(GRCh37/hg19, CEU; 1000 Genomes Project 2012) are shown as light blue lines. Genes are indicated below the LocusZoom plot. D, Fine 
mapping of whole-genome sequencing (WGS; MAF>0.05) based on LD and imputed SNPs from the arrays was used to narrow the TOF 
signal to a 104.7 Kb region (chromosome 5 [chr5]: 90 057 563–90 162 285) as shown. Most of the common SNPs from this region have P val-
ues <10−5. ARRDC3 indicates Arrestin domain containing 3; CETN3, Centrin 3; CEU, Northern Europeans who are Utah residents part of the 
CEPH collection; GPR98, G-protein–coupled receptor V1; LYSMD3, LysM, putative peptidoglycan-binding, domain containing 3; MBLAC2, 
Metallo-β-lactamase domain containing 2; MEF2C, Myocyte-specific enhancer factor 2C; and POLR3G, RNA polymerase III subunit G.
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to be done to provide additional support of the role of CETN3 
as a modifier of TOF in these individuals.
Among the remaining 5 genes (MEF2C, POLR3G, MBLAC2, 
LYSMD3, and ARRDC3), MEF2C is of particular interest because 
it encodes a transcription factor required in the second heart field 
mesoderm of the pharyngeal apparatus during embryogenesis 
for cardiac OFT development.41,42 Because haploinsufficiency of 
TBX1 is important for 22q11.2DS, and both MEF2C and TBX1 
are expressed in the second heart field progenitor cells, it is possi-
ble that TBX1 might act in the same genetic pathway as MEF2C. 
Further, studies in mouse models indicate that Tbx1 may be a 
negative regulator of Mef2c.43 This suggests that genetic variants 
in the 5q14.3 locus that may be associated with MEF2C expres-
sion levels could act as genetic modifiers of 22q11.2DS, with the 
A
B
C
Figure 3. Representative heatmap of 
chromatin conformation for the MEF2C 
(Myocyte-specific enhancer factor 2C)-
GPR98 (G-protein–coupled receptor V1) 
interval and in situ hybridization of selected 
genes in mouse embryos. A, Chromatin 
conformation map extracted from Hi-C 
data for the human lymphoblastoid cell line, 
GM12878, from the HapMap sample set.29 
Similar results were found using other cell 
types (Figure III in the Data Supplement). 
The intensity of each pixel represents the 
normalized number of contacts between a 
pair of loci. The purple line marking the tri-
angle depicts the contact domain31 between 
the GPR98 and the MEF2C locus. B, Lateral 
views of E9.5 and E10.5 wild-type embryos 
following in situ hybridization of antisense 
probes for Gpr98, Cetn3 (Centrin 3), Mef2c, 
and Lysmd3 (LysM, putative peptidoglycan-
binding, domain containing 3). Purple color 
indicates mRNA expression. C, Bar graph of 
relative gene expression levels from Affyme-
trix microarrays for the microdissected 
distal pharyngeal apparatus from E9.5 stage 
mouse embryos (y axis). Individual genes are 
shown for comparison, including representa-
tive housekeeping genes with high expres-
sion (Actb, Gapdh), genes on chromosome 
5q14.3 (Cetn3, Arrdc3, Mef2c, Polr3g, 
Lysmd3, Mblac2, and Gpr98) and represen-
tative low expressing genes (Il6, Olfr299), in 
descending order according to expression. A 
indicates anterior; Arrdc3 indicates Arrestin 
domain containing 3; Cetn3, Centrin 3; FB, 
forebrain; H, heart; HB, hindbrain; Lysmd3, 
LysM, putative peptidoglycan-binding, 
domain containing 3; Mblac2, Metallo-β-
lactamase domain containing 2; OFT, car-
diac outflow tract; P, posterior; Polr3g, RNA 
polymerase III subunit G; and S, somites.
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caveat that causation will require direct experimental support. 
Further, ISL1 transcription factor (ISL LIM homeobox 1 tran-
scription factor) and GATA (transcription factor) proteins bind 
and regulate both Mef2c and Nkx2-5 (NK2 homeobox 5 tran-
scription factor) cardiac development genes.44 One hypothesis to 
test in the future by direct experimentation would be that rare 
DNA variants in MEF2C, ISL1, or NKX2-5 affect cardiac OFT 
formation in individuals with 22q11.2DS.
In recent years, higher-order chromatin structure technol-
ogies have demonstrated that chromatin interactions occur in 
a nonrandom manner along the chromosome arms, which are 
separated into regions of highly interacting chromatin.30,45–47 
Relevant to this, the 104.7 kb region found with top associated 
SNPs to TOF shows a possible regulatory connection with 
MEF2C located 2 Mb upstream of GPR98 using available 
Hi-C, chromatin conformation data.29 One limitation of using 
Hi-C data to draw conclusions about gene regulation is that 
these data indicate that the 2 genes may reside within the same 
topological region but do not prove that there is a definitive 
regulatory connection. Further chromatin conformation data 
in cell progenitors relevant to cardiac OFT development, fol-
lowed by direct experimental approaches, will be required to 
define this interaction further. In addition, a better understand-
ing of the regulatory landscape in this region will be needed 
to identify the mechanism(s) responsible for the association to 
TOF we have observed in the 5q14.3 region.
Further support for MEF2C, as a possible modifier gene, 
comes from a recent GWAS of circulating VEGF (vascular 
endothelial growth factor) levels in blood in adults.48 Although 
this is a study of adults, factors that regulate VEGF levels may 
be similar throughout life and could affect fetal development. 
Previously, it was found that absence of one of the VEGF 
isoforms causes a phenocopy of 22q11.2DS in mouse mod-
els.49 In this recent GWAS of VEGF levels in adults, MEF2C 
and JMJD1C (Jumonji domain containing 1C) were found 
among the 6 loci with significant association to VEGF lev-
els. JMJD1C is relevant because we previously found signifi-
cant enrichment of rare predicted exonic variants in JMJD1C 
in whole-exome sequence from 184 22q11.2DS subjects in 
which the cases were enriched for TOF.50 This provides a 
potential biological connection between common and previ-
ous rare variant analyses for 22q11.2DS. However, in regards 
to the general population, neither haploinsufficiency nor 
mutation of MEF2C in humans has been associated with any 
type of CHD thus far.51–53 Further proof that MEF2C is a car-
diac disease gene in the general population will require future 
genetic studies.
The number of samples we obtained, even after 25 years 
of collection, is quite small for a GWAS of a complex trait. 
Thus, one of the limitations of the study was the lack of a true 
replication cohort. Another limitation of our study is possible 
population stratification. The majority of our cohort was self-
reported as white. Nevertheless, a subset had different ethnici-
ties requiring statistical correction in the analysis. Further, we 
examined each ethnicity separately and combined each group 
by performing a meta-analysis. We found that the top SNP in 
GPR98 was still statistically significant. In addition, the odds 
ratio was in the same direction in all the subcohorts, support-
ing our findings despite the limitations.
In this report, we used available bioinformatic data to 
interpret our data. However, this study did not provide proof of 
causation. This will need to be done by performing functional 
studies including development of animal models. Despite the 
limitations of the study, this is the first GWAS to identify com-
mon variants that may modify the cardiac phenotype in a large 
cohort of individuals with 22q11.2DS.
Conclusions
A GWAS of TOF in 22q11.2DS has identified a significant 
locus on 5q14.3 harboring potential genetic risk factors. Sev-
eral genes reside in this locus including MEF2C that is a known 
gene for cardiac OFT development in animal models. Further 
work needs to be done to ascertain whether MEF2C or other 
genes in this region act as modifiers of TOF in 22q11.2DS.
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CLINICAL PERSPECTIVE
The 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) occurs in 1 of 4000 live births, and 60% to 
70% of affected individuals have congenital heart disease, ranging from mild to severe. In our cohort of 1472 subjects with 
22q11.2 deletion syndrome, a total of 62% (n=906) have congenital heart disease and 36% (n=326) of these have tetralogy 
of Fallot, comprising the largest subset of severe congenital heart disease in the cohort. One of the main questions clinicians 
are interested in understanding is the basis for variable phenotypic expression. To address this question, using 22q11.2 dele-
tion syndrome as a model, we performed a genome-wide association study and found tetralogy of Fallot was significantly 
associated with a genetic interval on chromosome 5q14.3. The associated region is within an intron of GPR98. This intron 
may contain regulatory sequences that could effect expression of GPR98 or other genes in the region. Among them, MEF2C 
(Myocyte-specific enhancer factor 2C) is the only gene that is known to affect heart development. On the basis of this work, 
common DNA variants on 5q14.3 may explain, in part, why phenotypic variation occurs despite the fact that they have the 
same deletion. Further work will need to be done to determine whether the same genetic variants can alter MEF2C expres-
sion and risk for congenital heart disease in the general population or alter clinical outcomes. In the future, understanding 
how genetic variations influence phenotype in both genetic syndromes and in more common disease will make it possible to 
improve genetic counseling, rehabilitation, clinical outcomes, and in the creation of novel therapeutics.
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